AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By Ariana Sutherland
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By Ariana Sutherland
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By Ariana Sutherland
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Sunvozertinib and Selpercatinib Move the Needle in Molecularly Defined Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
ASCO 2026: Sunvozertinib and Selpercatinib Move the Needle in Molecularly Defined Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
ASCO 2026: Sunvozertinib and Selpercatinib Move the Needle in Molecularly Defined Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.